Timothy You, MD
Ophthalmology · Santa Ana, CANPI 1326041880
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (50.9%), food and beverage and speaking fees — rather than concentrated in one kind of arrangement. 34 manufacturers reported payments, led by Bausch & Lomb Americas Inc. at 28.3% of the total. Reporting peaked in 2022 at $21,527 and has fallen 73.1% since, to $5,799 in 2025. Among ophthalmology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 560 payments — averaging $97.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bausch & Lomb Americas Inc.$16K
- Genentech USA, Inc.$13K
- AbbVie$10K
- Alcon$3K
- Regeneron Healthcare Solutions, Inc.$2K
- Mallinckrodt Hospital Products Inc.$2K
- plus $9K from 28 others
Across 24 payments — averaging $23,065 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Apellis Pharmaceuticals, Inc.$251K
- Topcon Healthcare Solutions, Inc.$176K
- Topcon Healthcare, Inc.$117K
- Topcon Corporation$8K
- Thrombogenics, Inc.$1K
What the payments were for
- Consulting fees$27,89051%
- Speaking & faculty fees$8,32315%
- Travel & lodging$1,4493%
- Food & beverage$16,87231%
- Education$180%
- Entertainment$2891%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bausch & Lomb Americas Inc. | 41 | $15,524 |
| Genentech USA, Inc. | 69 | $12,929 |
| AbbVie(2 entities) | 113 | $10,380 |
| Alcon | 32 | $3,341 |
| Regeneron Healthcare Solutions, Inc. | 69 | $2,322 |
| Mallinckrodt Hospital Products Inc. | 64 | $1,746 |
| Cardinal Health 108 LLC | 1 | $1,575 |
| Apellis Pharmaceuticals, Inc. | 32 | $1,155 |
| Notal Vision, Inc. | 3 | $898 |
| Novartis | 11 | $708 |
| Astellas Pharma US Inc | 27 | $662 |
| Alimera Sciences, Inc. | 13 | $607 |
| Genentech, Inc. | 6 | $352 |
| Aerie Pharmaceuticals, Inc. | 12 | $298 |
| Samsara Vision | 3 | $296 |
| Optos, Inc. | 4 | $289 |
| ANI Pharmaceuticals, Inc. | 13 | $227 |
| Astellas Pharma Global Development | 3 | $200 |
| Regeneron | 2 | $161 |
| Harrow Eye, LLC | 6 | $153 |
| Amgen(2 entities) | 8 | $150 |
| Oyster Point Pharma, Inc. | 4 | $117 |
| Thrombogenics, Inc. | 1 | $117 |
| Biogen | 6 | $116 |
| Ivantis, Inc | 2 | $112 |
| Sight Sciences, Inc. | 1 | $97 |
| Coherus Oncology, Inc. | 3 | $74 |
| Neurotech Pharmaceuticals, Inc. | 3 | $64 |
| Eyepoint US, Inc. | 2 | $59 |
| Sun Pharmaceutical Industries Inc. | 2 | $48 |
| Rayner Intraocular Lenses Limited | 1 | $24 |
| Thea Pharma Inc. | 1 | $21 |
| Spark Therapeutics, Inc. | 1 | $19 |
| Travere Therapeutics, Inc. | 1 | $1 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$54,841 in reported general payments places this provider in the 95th percentile of 2,513 ophthalmology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 59 | $50,962 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 99 | $20,179 |
| XiidraLifitegrast | 14 | $15,313 |
| Prednisolone Acetate | 414 | $13,940 |
| Cyclosporine | 33 | $13,788 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 93 | $11,857 |
| Alphagan PBrimonidine Tartrate | 24 | $11,844 |
| RhopressaNetarsudil Mesylate | 21 | $8,474 |
| LumiganBimatoprost | 18 | $7,820 |
| Loteprednol Etabonate | 45 | $7,635 |
| CombiganBrimonidine Tartrate/Timolol | 20 | $4,660 |
| Brimonidine Tartrate | 141 | $3,001 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 101 | $1,493 |
| Atropine Sulfate | 39 | $1,336 |
| MoxifloxacinMoxifloxacin Hcl | 59 | $1,285 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Alphagan P, Lumigan, Combigan | $10,380 | $75,287121 claims |
| AlconSimbrinza | $3,341 | $20,17999 claims |
| Bausch & Lomb Americas Inc.Xiidra | $15,524 | $15,31314 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa | $298 | $8,47421 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,513 ophthalmology providers in California.
Other ophthalmology in Santa Ana
- Daniel SchwartzSan Francisco$8M
- Michael BerlinWest Hollywood$5.7M
- Gilbert KlimanMenlo Park$1.5M
- Kuldev SinghStanford$1.5M
- Raymond DouglasBeverly Hills$1.3M
- John AffeldtLoma Linda$1.1M
- Srinivas SaddaPasadena$1M
- Sheri RowenNewport Beach$1M
- Savak TeymoorianLaguna Hills$955K
- Andrew MoshfeghiLos Angeles$895K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.